This funding opportunity supports projects advancing Strep A vaccine development to prevent rheumatic heart disease, emphasizing early clinical trials, controlled human infection models, epidemiology, immunology, preclinical models, and regulatory preparation. Projects must have a plausible connection to reducing RHD and align with current funding priorities.
Eligible projects are those across the vaccine development pipeline aligned with current funding priorities and plausibly connected to reducing rheumatic heart disease, beyond other Strep A disease manifestations.
